This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
SLC12A1 · Western blot design guide
SLC12A1 Western Blot Planning Guide
Plan a SLC12A1 Western blot around the catalog-observed 121.5 kDa band, image-backed PA2168 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
SLC12A1 Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 121.5 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 8-10% | |
| Positive control | Kidney | |
| Negative control | Adipose tissue |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 121.5 kDa |
| ⓘ | Localization | Apical cell membrane |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Rat / Mouse / Human |
Section 1
Real Curated SLC12A1 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Kidney |
| Gel % | 8-10% |
| Load | 20-30 µg total protein per lane |
| Transfer | Wet/tank, extended transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | PA2168 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected SLC12A1 Western Blot Band Size?
Use the product-observed 121.5 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 121.5 kDa | Matches the authoritative product WB observation. |
| 121.5 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected SLC12A1 appearancePlan around 121.5 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 121.5 kDa; use this as the primary experimental expectation. |
| Calculated mass | 121.5 kDa from UniProt Q13621; retain as context. |
| Gel selection | 8-10%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with PA2168. |
| Situation | Likely cause | Next action |
|---|---|---|
| 121.5 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing SLC12A1 band
PA2168 · SLC12A1
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for SLC12A1 Western blot
🧪Use Kidney as the first positive-control candidate and Adipose tissue as the HPA Not detected negative candidate.
Positive control: Kidney (High)
Negative control: Adipose tissue (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for SLC12A1
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Section 3
Advanced SLC12A1 Western Blot Tips
Deeper troubleshooting and optimisation questions for SLC12A1, answered from its protein features.
Which band should guide the blot?
Use 121.5 kDa, the observation attached to the authoritative PA2168 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 121.5 kDa expectation.
Which positive control should I start with?
Start with Kidney, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Adipose tissue as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 8-10% consistently across the quick facts, protocol table, and poster.
What transfer method to use for SLC12A1 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PA2168 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
SLC12A1 Western Blot Reagents
Rat/Mouse/Human-reactive SLC12A1 Western blot reagents with authoritative product imagery.
Real WB data
Anti-SLC12A1 Antibody Picoband®
Cat # PA2168
Real WB data
Anti-SLC12A1 Antibody Picoband®
Cat # PB9392
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt Q13621
- Human Protein Atlas — SLC12A1
- PA2168 product record
- PMC5288206 — Treatment with an SLC12A1 antagonist inhibits tumorigenesis in a subset of hepatocellular carcinomas (Oncotarget, 2016)
- PMC7718005 — Integrated Analysis of m6A Methylome in Cisplatin-Induced Acute Kidney Injury and Berberine Alleviation in Mouse (Frontiers in genetics, 2020)
- PMC5016959 — A missense mutation in solute carrier family 12, member 1 (SLC12A1) causes hydrallantois in Japanese Black cattle (BMC genomics, 2016)